Equities analysts forecast that Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) will announce earnings per share of ($0.54) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Bellicum Pharmaceuticals’ earnings. The highest EPS estimate is ($0.46) and the lowest is ($0.61). Bellicum Pharmaceuticals posted earnings of ($0.61) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 11.5%. The business is expected to announce its next quarterly earnings report on Tuesday, March 12th.
On average, analysts expect that Bellicum Pharmaceuticals will report full year earnings of ($2.40) per share for the current fiscal year, with EPS estimates ranging from ($2.68) to ($2.26). For the next fiscal year, analysts forecast that the firm will post earnings of ($2.01) per share, with EPS estimates ranging from ($2.26) to ($1.60). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Bellicum Pharmaceuticals.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last announced its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.03. The firm had revenue of $0.29 million for the quarter, compared to the consensus estimate of $0.07 million.
Several research firms recently issued reports on BLCM. ValuEngine upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 10th. BidaskClub upgraded Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 14th. Citigroup reduced their price target on Bellicum Pharmaceuticals from $22.00 to $19.00 and set a “buy” rating on the stock in a research report on Thursday, August 9th. Finally, Zacks Investment Research upgraded Bellicum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a research report on Friday, November 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $13.42.
In related news, Director Jon P. Stonehouse purchased 10,000 shares of Bellicum Pharmaceuticals stock in a transaction that occurred on Friday, November 9th. The shares were acquired at an average cost of $4.56 per share, for a total transaction of $45,600.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at $45,600. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 9.84% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA grew its position in Bellicum Pharmaceuticals by 161.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 16,949 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 10,466 shares during the last quarter. Swiss National Bank lifted its holdings in Bellicum Pharmaceuticals by 32.3% in the 2nd quarter. Swiss National Bank now owns 58,600 shares of the biopharmaceutical company’s stock worth $432,000 after buying an additional 14,300 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in Bellicum Pharmaceuticals in the 3rd quarter worth approximately $110,000. Vanguard Group Inc. lifted its holdings in Bellicum Pharmaceuticals by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 1,947,842 shares of the biopharmaceutical company’s stock worth $11,999,000 after buying an additional 23,410 shares during the period. Finally, Jefferies Group LLC lifted its holdings in Bellicum Pharmaceuticals by 117.9% in the 3rd quarter. Jefferies Group LLC now owns 46,799 shares of the biopharmaceutical company’s stock worth $288,000 after buying an additional 25,325 shares during the period. Institutional investors and hedge funds own 56.13% of the company’s stock.
BLCM opened at $4.55 on Thursday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 8.01 and a current ratio of 8.01. Bellicum Pharmaceuticals has a 1 year low of $3.88 and a 1 year high of $10.26. The company has a market cap of $197.29 million, a P/E ratio of -1.60 and a beta of 1.10.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
Recommended Story: What are different types of coverage ratios?
Get a free copy of the Zacks research report on Bellicum Pharmaceuticals (BLCM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.